Roche’s Q4 sales grew by 3% at CER (all sales numbers at CER unless specified) to CHF13.1bn. The deviation from our forecasts segment-wise were balanced at the net level – the better performance by the pharma business (+3% vs 2% in Q3) ironed out marginal underperformance in the diagnostics business (+5% vs 8% in Q3). For the full year, Pharma grew by 3% and Diagnostics by 7%, stepping up to group sales growth of 4% to CHF50.6bn. By therapeutic area for the year, oncology (64% of
20 Mar 2017
Newsflow on pipeline and biosimilar development to be more meaningful this year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Newsflow on pipeline and biosimilar development to be more meaningful this year
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
20 Mar 2017 -
Author:
Kamla Singh -
Pages:
4
Roche’s Q4 sales grew by 3% at CER (all sales numbers at CER unless specified) to CHF13.1bn. The deviation from our forecasts segment-wise were balanced at the net level – the better performance by the pharma business (+3% vs 2% in Q3) ironed out marginal underperformance in the diagnostics business (+5% vs 8% in Q3). For the full year, Pharma grew by 3% and Diagnostics by 7%, stepping up to group sales growth of 4% to CHF50.6bn. By therapeutic area for the year, oncology (64% of